Curasight Valuation
Is CURAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CURAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CURAS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CURAS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CURAS?
Key metric: As CURAS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is CURAS's PB Ratio? | |
|---|---|
| PB Ratio | 17.6x |
| Book | DKK 13.31m |
| Market Cap | DKK 234.75m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -6.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CURAS's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.6x | ||
LIPUM Lipum | 7.4x | -22.2% | SEK 352.1m |
INIT Initiator Pharma | 13.5x | -40.0% | SEK 393.7m |
CANTA Cantargia | 6.8x | -3.4% | SEK 334.3m |
ALZ Alzinova | 2.6x | -39.4% | SEK 340.6m |
CURAS Curasight | 17.6x | n/a | DKK 234.7m |
Price-To-Book vs Peers: CURAS is expensive based on its Price-To-Book Ratio (17.6x) compared to the peer average (7.6x).
Price to Book Ratio vs Industry
How does CURAS's PB Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: CURAS is expensive based on its Price-To-Book Ratio (17.6x) compared to the Swedish Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is CURAS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 17.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CURAS's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
PMD Device Solutions
SEK 35.3m
A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.
PMDS
SEK 1.36
7D
-2.9%
1Y
n/a
Camurus
SEK 32.6b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.
CAMX
SEK 553.50
7D
0.6%
1Y
22.2%
Corline Biomedical
SEK 137.5m
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
CLBIO
SEK 6.40
7D
-7.5%
1Y
-48.2%